Dapagliflozin for fatty liver in hypothyroidism
Treatments studied
Part of Digestive system, Hormones & metabolism clinical trials.
This trial tests whether a medicine called dapagliflozin can help people with hypothyroidism (low thyroid function) who also have fatty liver disease (MASLD). It aims to see if this drug can reduce liver fat and improve liver health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have primary overt hypothyroidism (low thyroid hormones and high TSH).
- You do not have diabetes (type 1 or type 2).
- You do not have other liver diseases (like hepatitis, autoimmune hepatitis, or Wilson's disease).
- You are not pregnant or breastfeeding.
- You are not already taking vitamin E or pioglitazone.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether having an underactive thyroid can affect the build-up of scar tissue in the liver in people with a condition called MASLD (fatty liver disease linked to metabolic problems). If you have both underactive thyroid and fatty liver, this could help us understand your risk for liver damage.
This study tests if lowering insulin levels can reduce fat buildup in the liver for people with a fatty liver condition called MASLD. It's looking for adults who are overweight and have early signs of insulin resistance but not diabetes.
This study looks at the connection between thyroid problems (especially when the thyroid doesn't make enough hormone) and a common liver condition where fat builds up in the liver. Researchers want to understand how these two conditions relate to each other in people without diabetes.
This study tests whether a medication called henagliflozin can help reduce liver scarring (fibrosis) in people who have both fatty liver disease (MASLD) and type 2 diabetes. It is for those whose liver stiffness and blood sugar levels are in a certain range.
This trial studies whether erugliflozin can reduce liver fat and liver scarring (fibrosis) while also improving blood sugar in people with type 2 diabetes and fatty liver disease (NASH/NAFLD). It’s designed for people who haven’t used certain diabetes medicines like SGLT2 inhibitors or insulin before.
This trial tests whether adding dapagliflozin to metformin affects a hormone called IGF-1, which is linked to growth and metabolism. It may help men with type 2 diabetes and fatty liver disease understand if this combination can improve their condition.
Hear when a new Hepatic Steato-Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.